WASHINGTON, Sept. 14 (DC Times Online) — People taking GLP-1 drugs such as Wegovy, Ozempic, Zepbound and Mounjaro may have another issue to discuss with their clinicians if severe nausea, vomiting or appetite loss makes it hard to eat: a rare neurological condition tied to vitamin B1 deficiency.
A study reportedly published in the journal Clinical Nutrition identified 15 reported cases of Wernicke encephalopathy among people taking GLP-1 receptor agonists. The cases came from the U.S. Food and Drug Administration’s Adverse Event Reporting System, published medical reports and records from the researchers’ medical center, according to reports describing the study.
The findings do not show that the medications caused the condition. The study’s reported data also do not establish how often Wernicke encephalopathy occurs among GLP-1 users or the risk for an individual patient.
What is Wernicke encephalopathy?
Wernicke encephalopathy is a brain disorder caused by a severe shortage of thiamine, also called vitamin B1. Medical descriptions cited in reports about the study include confusion, problems with balance or walking, unusual eye movements and vision changes.
Without prompt treatment, the condition can cause lasting neurological damage or death, according to clinical experts quoted in the reports. Because early symptoms can overlap with the effects of illness, dehydration or poor nutrition, the condition can be difficult to recognize without medical evaluation.
Thiamine is found in foods including meat, beans and fortified grains. The body needs it to help process energy. The reports about the study propose that severe reductions in food intake, rather than a direct effect on the brain from GLP-1 drugs, may help explain the cases.
How could the drugs be involved?
GLP-1 drugs act on hormone pathways involved in blood sugar, digestion and appetite. Semaglutide is sold under the brand names Ozempic, Wegovy and Rybelsus. Tirzepatide is sold as Mounjaro and Zepbound. One reported case involved liraglutide, sold as Victoza.
The drugs can cause gastrointestinal side effects, including nausea and vomiting, and they can reduce appetite. Researchers and clinicians quoted in the reports said those effects may leave some people eating too little to obtain enough thiamine and other nutrients.
Achari, an expert quoted in the reports, said, “The drug shrinks your appetite. It doesn’t shrink your body’s requirements.” Achari also identified persistent nausea or vomiting, rapid weight loss while eating little, previous bariatric surgery and heavy alcohol use as possible risk factors.
Those factors describe a proposed pathway, not a confirmed explanation for every reported case. The available reports do not provide the full medical histories, dosages or treatment details for all 15 people.
What did the study find?
The 15 cases were identified in an analysis of 195,979 reports, according to accounts of the study. The reports said Wernicke encephalopathy appeared disproportionately among people taking GLP-1 drugs compared with other medications.
That comparison should not be read as a personal risk estimate. Adverse-event databases collect reports of health problems after drug exposure, but they do not show how many people took the drug without developing the condition. They can also be affected by incomplete reporting, changes in drug use and other differences between patients.
The information available does not provide an incidence rate, an absolute risk, a formal relative-risk estimate or a confidence interval. It also does not establish whether the 15 cases overlap with other published case reports.
A separate review reportedly examined six published cases involving people treated with semaglutide for obesity. The review described four women and two men, with a mean age of 47 and symptoms appearing after an average of 4.9 months of treatment. It reported one death, four cases of lasting memory impairment and one full recovery. That review is a separate evidence set and should not be combined with the 15-case analysis.
Should patients stop taking the drugs?
Experts quoted in the reports said patients should not stop prescribed GLP-1 medication solely because of the findings. They called for further research and clinical vigilance instead.
Dr. Goldman, quoted in one report, said GLP-1 medications are “among the most effective and important tools we currently have for treating obesity and diabetes,” adding that most patients take them safely.
The reported cases do suggest why severe or persistent vomiting, marked appetite loss, rapid weight loss while eating very little or signs of confusion and difficulty walking should be discussed promptly with a health professional, particularly when a person has other risks for thiamine deficiency. The available material does not provide federal guidance requiring routine vitamin monitoring for all GLP-1 users.
The FDA’s adverse-event database is one source used to detect possible safety signals. A report in that database does not by itself prove that a medication caused an illness. The FDA’s formal assessment, any regulatory response and current prescribing-label language about Wernicke encephalopathy or thiamine deficiency were not provided in the available records.
